IDENTIFICATION OF PIPERAZINYLBENZENESULFONAMIDES AS NEW INHIBITORS OF CLAUDIN-1 TRAFFICKING AND HEPATITIS C VIRUS ENTRY
Journal of virology, 2018.
Hepatitis C virus (HCV) infection causes 500,000 deaths annually, associated with end-stage liver diseases. Investigations of the HCV life cycle widened the knowledge in virology, and here we discovered that two piperazinylbenzenesulfonamides inhibit HCV entry into liver cells. The entry process of HCV into host cells is a complex process...More
Full Text (Upload PDF)